<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368520</url>
  </required_header>
  <id_info>
    <org_study_id>COLDstudy</org_study_id>
    <nct_id>NCT04368520</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Optimise Levels of Vitamin D for Rhinovirus Protection</brief_title>
  <official_title>Clinical Trial to Optimise Levels of Vitamin D for Rhinovirus Protection (COLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II randomised, placebo-controlled trial to identify the optimal regimen of vitamin D
      supplementation for rhinovirus protection, determined by host responses to a clinically
      induced rhinovirus challenge. The primary outcome is rhinovirus titre after inoculation with
      rhinovirus; secondary outcomes are self-reported respiratory symptom scores, concentrations
      of cytokines and chemokines sampled from the nasal mucosa, and the transcriptional responses
      of nasal epithelial cells.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two treatment arms of vitamin D3: low dose (800IU) vs. high dose (3,200IU) given daily, for 3 months</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rhinovirus titres</measure>
    <time_frame>+3 to +5 days after inoculation</time_frame>
    <description>PCR-detected rhinovirus-16 load sampled from the nasal mucosa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory symptom score (Jackson Score)</measure>
    <time_frame>+1 to +14 days after inoculation</time_frame>
    <description>Total self-reported respiratory symptom score (scored 0-32; increasing score equals increasing symptom severity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine and chemokine concentrations</measure>
    <time_frame>Day 0 and +4 days after inoculation</time_frame>
    <description>Change in concentrations of inflammatory mediators (Including, but not limited to IL-1β, IL-2, IL-4, IL-5, Il-6, IL- 7, IL-8 [CXCL8], IL-10, IL-12, IL-13, IL-15, IL-17, IL-1RA, IL-2R, IFN-α, IFN-γ, TNF-α, MCP-1 [CCL2], MIP- 1α [CCL3], MIP-1β [CCL4], RANTES [CCL5], eotaxin [CCL11], MIG [CXCL9], IP-10 [CXCL10], EGF, FGF-basic, HGF, VEGF, G-CSF, GM-CSF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of vitamin D-regulated gene expression</measure>
    <time_frame>Day 0 and +4 days after inoculation</time_frame>
    <description>Change in expression of DHCR7, CYP2R1, CYP3A4, CYP27A1, CYP27B1, CYP24A1, VDR, DBP, RXRA</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>800 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months</description>
    <arm_group_label>Low dose vitamin D3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>3,200 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months</description>
    <arm_group_label>High dose vitamin D3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Hypromellose capsules, given daily for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-70 years

          2. Gives written informed consent

          3. Serum 25-hydroxyvitamin D concentration &lt;75 nmol/L

          4. Agrees not to take supplement containing vitamin D during participation

          5. Agrees not to commence smoking or vaping during participation

        Exclusion criteria:

          1. Current smoker or vaper

          2. Taken vitamin D supplement or other supplement containing vitamin D, in previous 3
             months

          3. Sunny holiday abroadI, defined as any location 51 degrees North/South of the equator,
             for ≥1 week, in the previous 3 months

          4. Dependent(s) &lt;6 months old

          5. Positive serology for anti-RV16 antibodies

          6. Living with someone with severe airways disease

          7. Any of the following medical conditions:

               1. Diabetes mellitus

               2. Asthma

               3. Chronic Obstructive Pulmonary Disease

               4. Respiratory allergies

               5. Sarcoidosis

               6. Hyperparathyroidism

               7. Nephrolithiasis

               8. Active tuberculosis

               9. Liver failure

              10. Renal failure

              11. Lymphoma or other malignancy not in remission for ≥ 3 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David A Jolliffe, PhD</last_name>
    <phone>07920648370</phone>
    <email>d.a.jolliffe@qmul.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adrian R Martineau, PhD</last_name>
    <phone>0207 882 2551</phone>
    <email>a.martineau@qmul.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Sebastian L Johnston, PhD</last_name>
      <phone>020 7594 3764</phone>
      <email>s.johnston@imperial.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rhinovirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified IPD will be shared with other researchers subject to terms of Data Transfer Agreement and IRB approval</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>2 years after completion of the trial</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

